Drug

Narlumosbart clinical trials

Also written JMT103.

studies test it: 8
open now: 4
in phase 3: 3
first study started: 2020

How each study uses narlumosbart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the narlumosbart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Narlumosbart: 3

Development codes

JMT103: 5

Studies by the year they started

8 studies that test it; most in 2020 (2)

Studies that test narlumosbart, by start year
Year	Studies
2020	2
2022	2
2023	1
2024	2
2025	1

By phase

A phase 1/2 study counts in both.

Phase 1: 2
Phase 2: 4
Phase 3: 3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Multiple Myeloma: 1
Giant Cell Tumor of Bone: 1
Osteoporosis, Postmenopausal: 1

Who runs them

Industry 6 · Other 2

Shanghai JMT-Bio Inc. (6) · RenJi Hospital (1) · Fudan University (1)

Often tested with

Tested in the same studies.

Zoledronic Acid (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2, 1 in phase 3

Studies that test narlumosbart, phase 3 first.

May 2027A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic AcidPhase 3 · Shanghai JMT-Bio Inc.
Dec 2026The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung CancerPhase 2 · Fudan University

Studies

Open first, then newest update. How each study uses narlumosbart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 8

Codes

What other systems call narlumosbart · ClinicalTrials.gg INT016903

UNII (FDA) J38KT46AH8NARLUMOSBARTOne source FDA
NCI Thesaurus C190458NarlumosbartOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	J38KT46AH8	NARLUMOSBART	One source FDA
NCI Thesaurus	C190458	Narlumosbart	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.